Preferred Label : PD-1-positive B-cell Peptide Antigen/MVF IMU-201/Montanide Vaccine;
NCIt synonyms : IMU-201/Montanide Vaccine; PD1-Vaxx; PD-1-positive B-cell Peptide Antigen/Measles Virus Fusion Protein IMU-201/Montanide
Vaccine;
NCIt definition : A cancer vaccine consisting of the fusion peptide IMU-201, composed of the B-cell
epitope APi2568 (amino acids 92-110) derived from the extracellular domain (ECD) of
the negative immunoregulatory human cell receptor programmed cell death protein 1
(PD-1; PDCD1; CD279), linked to a promiscuous T-cell epitope derived from measles
virus fusion protein (MVF; amino acid residues 288-302) via a 4-amino acid linker
(Gly-Pro-Ser-Leu), and combined with the immunoadjuvant Montanide ISA 720, with potential
immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon
administration, IMU-201/montanide vaccine induces the production of polyclonal antibodies
against PD-1. In turn, the antibodies bind to PD-1, and inhibit PD-1 and its downstream
signaling pathways. This may restore immune function through the activation of T-cells
and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein
in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune
checkpoint that negatively regulates T-cell activation and effector function when
activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation
274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.;
NCI Metathesaurus CUI : CL1648149;
Origin ID : C178425;
UMLS CUI : C5555024;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
